Free Trial
NASDAQ:HOWL

Werewolf Therapeutics Q1 2025 Earnings Report

Werewolf Therapeutics logo
$1.79 -0.05 (-2.72%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$1.78 -0.01 (-0.61%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Werewolf Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.30 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Werewolf Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Werewolf Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 11:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Werewolf Therapeutics Earnings Headlines

Why More Investors Are Using Family Trusts to Protect Their Wealth
For many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest.tc pixel
See More Werewolf Therapeutics Headlines

About Werewolf Therapeutics

Werewolf Therapeutics (NASDAQ:HOWL) (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs. These investigational agents are engineered to engage key immune pathways—such as T-cell activation and pro-inflammatory cytokine signaling—only when proteolytically processed by enzymes present in the tumor milieu. This approach is intended to drive a potent, localized immune response against cancer cells while reducing the risk of adverse events associated with systemic cytokine exposure.

The company’s pipeline spans both preclinical and early clinical stages, with lead programs targeting interleukin and tumor-necrosis factor family members. In addition to internal research efforts, Werewolf Therapeutics collaborates with academic institutions and industry partners to explore combination regimens that may further enhance the anti-tumor activity of its conditional agents.

Founded in 2019 and headquartered in Cambridge, Massachusetts, Werewolf Therapeutics is led by a management team with extensive experience in immuno-oncology drug discovery and clinical development. The company is focused on advancing its pipeline through regulatory milestones and clinical proof-of-concept studies in the United States.

View Werewolf Therapeutics Profile

More Earnings Resources from MarketBeat